{"groups":[{"description":"Intravenous Pro-netupitant/Palonosetron (260 mg/0.25 mg) powder for solution for infusion (on Day 1) with oral dexamethasone prior to each scheduled chemotherapy cycle\n\nPro-netupitant/Palonosetron\n\nDexamethasone","id":"FG000","title":"Pro-netupitant/Palonosetron Plus Dexamethasone"},{"description":"Oral netupitant/palonosetron (300 mg/0.50 mg) hard capsule (on Day 1) with oral dexamethasone prior to each scheduled chemotherapy cycle\n\nNetupitant/Palonosetron\n\nDexamethasone","id":"FG001","title":"Netupitant/Palonosetron Plus Dexamethasone"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"203"},{"groupId":"FG001","numSubjects":"202"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"120"},{"groupId":"FG001","numSubjects":"117"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"83"},{"groupId":"FG001","numSubjects":"85"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}